Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects

NCT04809818 is registered in ClinicalTrials.gov with Lumosa Therapeutics Co., Ltd. as lead sponsor.

NCT NCT04809818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04809818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 21, 2021
Completion date
August 5, 2021
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke